CenterBook Partners LP lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 66.5% in the 4th quarter, Holdings Channel reports. The fund owned 3,058 shares of the medical research company’s stock after selling 6,071 shares during the quarter. CenterBook Partners LP’s holdings in Bio-Rad Laboratories were worth $927,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Danske Bank A S bought a new stake in Bio-Rad Laboratories in the fourth quarter worth $30,000. Geneos Wealth Management Inc. increased its holdings in Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Bio-Rad Laboratories in the 4th quarter worth $47,000. Farther Finance Advisors LLC raised its stake in shares of Bio-Rad Laboratories by 76.9% in the fourth quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock worth $56,000 after buying an additional 80 shares during the period. Finally, Financial Management Professionals Inc. purchased a new stake in Bio-Rad Laboratories in the 4th quarter worth approximately $61,000. 65.24% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have commented on the stock. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research note on Friday, May 1st. Weiss Ratings cut Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 6th. Royal Bank Of Canada started coverage on shares of Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 price objective for the company. Finally, Citigroup lowered shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $375.00 to $300.00 in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $303.33.
Bio-Rad Laboratories Trading Down 1.9%
Shares of BIO opened at $291.63 on Thursday. Bio-Rad Laboratories, Inc. has a 1-year low of $222.80 and a 1-year high of $343.12. The company has a 50-day moving average of $283.48 and a 200 day moving average of $291.36. The firm has a market capitalization of $7.80 billion, a price-to-earnings ratio of 48.04 and a beta of 1.08. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37.
Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The company had revenue of $592.10 million for the quarter, compared to the consensus estimate of $589.91 million. During the same quarter in the previous year, the business earned $2.54 EPS. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 9.42 EPS for the current year.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.
Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.
Featured Stories
- Five stocks we like better than Bio-Rad Laboratories
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
